Kyoto University Innovation Capital
Kyoto University Innovation Capital Co., Ltd. (Kyoto iCAP) is a venture capital firm established in December 2014, wholly funded by Kyoto University. Located in Kyoto, Japan, the firm focuses on providing investment and support to startups emerging from Kyoto University, with an emphasis on commercializing research outcomes and technologies developed by its researchers. Kyoto iCAP specializes in various sectors, including healthcare, medical devices, biotechnology, drug discovery, internet of things, artificial intelligence, machinery, clean technology, energy, new materials, food, and agriculture. The firm aims to bridge the gap between academic research and marketable innovations, fostering the growth of spin-off companies that leverage the university's intellectual assets.
Top Stages
Past deals in Nanotechnology
Enu Pharma
Seed Round in 2024
Enu Pharma is a pharmaceutical company focused on innovative research and the development of advanced medicines aimed at improving global healthcare standards. The company specializes in nanosome technology, which is designed to assist medical professionals in treating intractable diseases. This technology features core metals enveloped in an antiadhesive mixed self-assembled monolayer, which helps prevent the non-specific surface protein corona that can hinder drug efficacy. By leveraging this unique approach, Enu Pharma aims to enhance drug discovery, development, and delivery, ultimately contributing to more effective treatment options for challenging medical conditions.
RadioNano Therapeutics
Series A in 2024
RadioNano Therapeutics is developing innovative drugs for Boron Neutron Capture Therapy (BNCT), a type of radiation therapy that utilizes the nuclear reaction between thermal neutrons and boron-10 (¹⁰B) to destroy cancer cells by releasing alpha particles and lithium nuclei.
RadioNano Therapeutics
Seed Round in 2024
RadioNano Therapeutics is developing innovative drugs for Boron Neutron Capture Therapy (BNCT), a type of radiation therapy that utilizes the nuclear reaction between thermal neutrons and boron-10 (¹⁰B) to destroy cancer cells by releasing alpha particles and lithium nuclei.
U-Map
Venture Round in 2020
U-MaP Co., Ltd. is a manufacturer based in Nagoya, Japan, specializing in aluminum nitride (AlN) whiskers designed for thermal management and heat dissipation applications. Established in 2016, the company originates from research initiatives at Nagoya University and focuses on commercializing advanced materials and processing technologies. U-MaP is committed to addressing global challenges in manufacturing by developing conductive materials with high thermal conductivity and insulating properties. This innovative approach aims to enhance product quality and sustainability across various industries, positioning U-MaP as a key player in the development of next-generation industrial materials.
Stem Cell & Device Laboratory
Series B in 2017
Stem Cell & Device Laboratory, Inc. is a research and development company based in Kyoto, Japan, focused on the manufacturing and sale of cells, devices, and integrated products that utilize cell materials for drug discovery applications. Founded in 2014, the company specializes in developing innovative scaffold materials that demonstrate functional and cell compatibility, particularly for studies involving pluripotent stem cells. By leveraging advanced micro-engineering and nanofabrication technologies, Stem Cell & Device Laboratory aims to contribute to advancements in cell application products that support the health and well-being of society.
NS Materials
Venture Round in 2017
NS Materials Corp. is a manufacturer and distributor of semiconductor-related equipment and systems, located in Chikushino-shi, Japan. The company focuses on the development of micro-space chemical technologies, particularly in the area of nano-phosphor for LED lighting. Additionally, NS Materials specializes in chemical synthesis technologies that aim to advance nanotechnology and biotechnology. By creating innovative tools and products, the company contributes to the promotion of a low-carbon society and seeks to significantly impact people's lives.
Stem Cell & Device Laboratory
Series A in 2016
Stem Cell & Device Laboratory, Inc. is a research and development company based in Kyoto, Japan, focused on the manufacturing and sale of cells, devices, and integrated products that utilize cell materials for drug discovery applications. Founded in 2014, the company specializes in developing innovative scaffold materials that demonstrate functional and cell compatibility, particularly for studies involving pluripotent stem cells. By leveraging advanced micro-engineering and nanofabrication technologies, Stem Cell & Device Laboratory aims to contribute to advancements in cell application products that support the health and well-being of society.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.